Matt Durstenfeld is an Assistant Professor of Medicine at the University of California, San Francisco and a general cardiologist at Zuckerberg San Francisco General. His research focuses on preventing and managing infection-associated cardiovascular disease; his other interests are in global cardiology, health equity, and advanced methods for robust observational research. As a team scientist, he loves working closely with mentors and collaborators from Cardiology, Infectious Diseases, and Pulmonology. His completed K12 career development award focused on mechanisms of cardiopulmonary phenotype Long COVID. His K23 Career Development Award is focused on cardiorespiratory fitness in HIV. He is also involved in clinical trials of lipid-lowering therapies in HIV, an immune-modulator for Long COVID, an over-encapsulated polypill for heart failure, cardiac rehabilitation for Long COVID, and a first-in-human COVID vaccine. He also conducts observational research to elucidate mechanisms of Long COVID and post-tuberculosis heart and lung disease and identify strategies to prevent heart disease among people with HIV.
User Profile Bio
